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Introduction
 made up of physiological lipids or synthetic
 SLN  : 50‐1000 nm
 first introduced by Muller et al in 1991 
 Therapeutic , cosmetic and dermal, diagnostic 
application
 Last few years as colloidal drug carriers
 Several advantage ,minimize disadvantage
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History:
4
 Solid lipid used for several in form of pellet in 
peroral administration
 Speicer  and coworker (1980) : solid lipid 
microparticle with high speed mixer
 Muller et al (1991):submicron size of  solid lipid 
with High pressure homogenization(SLN)
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TREND OF NANOPARTICLE
https://scholar.google.com/ last update:May2016
Colloidal carrier:
 Lipid emulsion
 Liposome
 Polymeric 
nanoparticle
6
advantages include:
 controlled drug release
 less toxic
 Protecting the labile and sensitive drugs from  
degradation
 ease of scale‐up 
 Low cost  
 physical stability
 lipophilic and hydrophilic compounds can be
delivered by SLN
 biodegradable     
 different administration routes
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Challenge(1):
 Entrapment  of water soluble drugs
Polymeric Lipid Hybrid Nanoparticles (PLN)
 Avoidance of Reticulo Endothelial System(RES)
coating with PEG,POLOXAMINE
` Stealth particle`
 Controlled release of drug: 
Nanostructured Lipid Carriers (NLC)
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GENERAL INGREDIENTS(2):
 Solid lipid     
triglycerides, partial glycerids
fatty acids, steroids ,waxes
physiological lipids decreases the danger 
of acute and chronic toxicity.
 Emulsifier
used to stabilize the lipid dispersion
prevent particle agglomeration
 water
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Lipids and emulsifiers used  for 
SLN
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W. Mehnert, K. Ma¨der / Advanced Drug Delivery Reviews 47 (2001) 165 –196
SLN Production(3):
 SLN can be produced by various techniques:
 High pressure homogenization
 High shear homogenization and ultrasound
 Microemulsion based SLN preparations
 Supercritical Fluid technology 
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High pressure 
homogenization:
 Powerful technique 
 pushes the liquid with high pressure (100-2000 
bar) through a narrow gap ranging a few microns.
 The fluid accelerates to a very high viscosity of 
over 1000 km/h.
 Very high shear stress and cavitation forces 
disrupt the particles down to submicron range. 
 5% - 40%: lipid content 
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Ultrasonication:
 high speed homogenization
 Initially techniques
 advantage :equipment used is commonly available
 problems: broader size 
metal contaminations
physical instability 
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Microemulsion based SLN 
preparation
 dilution of 
microemulsions
 The hot microemulsion 
is dispersed in cold 
water (2-3°C) under 
stirring.
 Lipid content are 
lower compare with 
the HPH
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Supercritical Fluid technology(4):
 novel technique
 fluid is :supercritical
pressure and temperature
exceed critical value
dissolve compound increase
 particles obtained as a dry powder
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advantage disadvantage
Hot  homogenization Smaller particle •temperature induce 
drug degradation 
• complexity of the 
crystallization
cold homogenization Larger particle sizes 
Ultrasonication
(high speed 
homogenization)
•Equipment used is 
very common
• No temperature 
induced drug 
degradation
•Potential metal 
contamination
•Broader particle size 
Micro emulsion based 
SLN preparations
Solvent less 
processing
Lipid content are 
lower
Supercritical Fluid 
technology
dry powder
Mild pr ssure and 
temperature
More expansive
Sterilization:
 Parenteral administration
 Autoclave: heat resistant drug
 Filtration: particle size below 200nm 
 gamma irradiation
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Drug release from SLN(5)
 drug in the outer 
shell and on the 
particle surface: 
released in the form 
of a burst
 The drug 
incorporated into 
the particle core 
:released in a 
prolonged way. 
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Drug release from SLN
 Higher temperatures and higher surfactant 
concentrations: increase the burst
 SLN can be produced surfactant free or using 
surfactants which are not able
to solubilizethe drug: avoid 
or minimize the burst
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CHARACTERIZATION OF 
SLN(6):
important parameters :
 particle size and zeta potential
 degree of crystallintity and lipid modification
 coexistence of additional colloidal structures
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Particle size:
 Photon correlation 
spectroscopy (PCS)
 dynamic light scattering
 detects size range of 3nm 
to 3μm 
 good tool to characterize 
nano-particles
 fluctuation of the 
intensity of the scattered 
light which is caused by 
particle movement
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Particle size:
 laser diffraction (LD) diffraction  angle on the 
particle radius 
Detect size range  of 100 
nm to 180 μm.
 detection of larger 
microparticle
 recommended to use PCS 
and LD simultaneously
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Morphological structure:
 Atomic force 
microscopy (AFM) 
 Obtains image quickly
 Observation of in situ
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Zeta potential :
zeta potential analyzer or zetameter.               
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Measurement of crystallinity, 
lipid  modification:
 related with drug 
incorporation and 
release rates
 Differential scanning 
calorimetry (DSC) 
 X-ray scattering
 Infrared and Raman 
spectroscopy
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coexistence of additional 
colloidal structures
 nuclear magnetic 
resonance (NMR) 
 electron spin resonance 
(ESR) 
 investigating dynamic 
phenomena
 characteristics of 
nanocompartments in 
colloidal lipid 
dispersions
 non-invasiveness 
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Application:
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 Drug loader
 A novel carrier for chemotherapy:
cancer
parasitic infections
tuberculosis
 potential new adjuvant for vaccines
 gene therapy
 central nervous system diseases 
 SLNs as cosmeceuticals
 potential agriculture application
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Drug loader(7-8):
 Many different drugs 
incorporated in SLN
 important point: 
loading capacity
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solubility of drug in 
melted lipid
 miscibility of drug 
melt and lipid melt
 chemical and physical 
structure of solid lipid 
matrix
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CHEMOTHERAPY(9):
CONVENTIONAL SLN
 Poor specificity
 Side effect 
 Drug resistance
 enhanced  permeability 
and retention(EPR)
 Active tumor targeting
 Encapsulation of 
chemotherapeutic drug 
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SLN in tubercular 
chemotherapy:
 Anti  tubercular drug(ATD)
 Oral administration
 Detected in plasma 8 days
 Drug Concentration Above or Minimum inhibitory 
concentration(MIC90)
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SLN in the parasitic 
chemotherapy:
 Malaria
 Leishmaniasis
 Tryanosomiasis
 Brain targeting by SLN
 Administered 
intravenously
 Enhanced uptake
 Higher concentration in 
serum
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SLN in cancer chemotherapy:
 first in‐vivo studies
 Yang et al in 1999
 Camptothecin is an anticancer
 camptothecin‐SLN(CA‐SLN)
 increased accumulation of CA‐SLN in brain,
heart and RES organs
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 Oyewumi et al
 PEG and folate coated SLN of gadolinium
 Increased cellular uptake and retention in cancer 
cell
 Bondi et al
 prepared NLC of anticancer drug temozolamide
 increase in the effect on human hepatocellular 
carcinoma cell line
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new adjuvant for vaccines(10):
 Adjuvant are used in vaccination
 enhance the immune response.
 Freund's complete adjuvant (FCA) and Freund's 
incomplete adjuvant (FIA) 
 SLN:   degraded more slowly            
lasting exposure to the immune system
good tolerability by the body.
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gene therapy(11):
 good specificity to target cell 
 higher efficacy for transfection of genetic material
 Viral vectors unwanted immune response
 non viral transfection  like dendrimers
peptide
cationic lipids
polymers and liposome 
low in‐vivo effectiveness
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gene therapy:
•first in‐vivo study
•Gasco et al evaluated the 
transfection capacity 
•SLN‐DNA vector in 
mice.
•prevent macrophage 
uptake
•Protein expression  for at 
least one week.
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central nervous system(4):
 inability of drugs to pass blood brain barrier 
(BBB)
 SLN: transport of  BBB and tissue distribution 
increase
 Fundaro et al, 2000:doxorubicin loaded stealth 
and non-stealth SLN
 stealth nanoparticles  in blood at higher 
concentrations than non-stealth SLN after 24 h 
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Toxicity aspects
 Well tolerated
 Metabolic pathway
 Particle size: No problem
peroral or transdermal  administration
and i.m. or s.c. injection
parenteral administration:
pyrogens must be checked
Particle size distribution: embolism
43Solid lipid nanoparticle-May 2016
In vivo fate:
 (a) administration route
 (b) interactions of the SLN with the biological 
surroundings: 
distribution processes:
adsorption of biological material
desorption of The microclimate of SLN component 
enzymatic processes:
lipases and esterases            
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